Northern Trust Corp boosted its position in Jounce Therapeutics Inc (NASDAQ:JNCE) by 3.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 189,363 shares of the company’s stock after purchasing an additional 5,604 shares during the quarter. Northern Trust Corp owned about 0.57% of Jounce Therapeutics worth $937,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC lifted its position in shares of Jounce Therapeutics by 29.0% during the 2nd quarter. Acadian Asset Management LLC now owns 376,090 shares of the company’s stock valued at $1,862,000 after acquiring an additional 84,557 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Jounce Therapeutics by 5.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 295,568 shares of the company’s stock valued at $1,384,000 after acquiring an additional 15,125 shares during the period. Prudential Financial Inc. lifted its position in shares of Jounce Therapeutics by 20.2% during the 2nd quarter. Prudential Financial Inc. now owns 250,234 shares of the company’s stock valued at $1,239,000 after acquiring an additional 42,011 shares during the period. Strs Ohio bought a new stake in shares of Jounce Therapeutics during the 2nd quarter valued at $470,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Jounce Therapeutics by 25.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 85,021 shares of the company’s stock valued at $421,000 after acquiring an additional 17,218 shares during the period. Institutional investors and hedge funds own 72.40% of the company’s stock.
A number of research firms have recently weighed in on JNCE. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Jounce Therapeutics in a research report on Sunday, August 11th. Zacks Investment Research upgraded Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research report on Saturday. Finally, ValuEngine downgraded Jounce Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 29th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. Jounce Therapeutics currently has an average rating of “Hold” and an average price target of $8.75.
Shares of Jounce Therapeutics stock traded up $0.06 during trading on Friday, reaching $4.06. 211,300 shares of the company’s stock were exchanged, compared to its average volume of 175,348. Jounce Therapeutics Inc has a 1-year low of $2.66 and a 1-year high of $7.35. The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.03 and a current ratio of 2.03. The firm’s 50-day moving average price is $3.49 and its 200 day moving average price is $4.28. The company has a market cap of $124.67 million, a P/E ratio of -4.83 and a beta of 3.51.
Jounce Therapeutics (NASDAQ:JNCE) last announced its earnings results on Thursday, November 7th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.24 by $0.66. The company had revenue of $119.45 million for the quarter, compared to analyst estimates of $99.97 million. Jounce Therapeutics had a negative return on equity of 29.64% and a negative net margin of 46.07%. As a group, equities research analysts predict that Jounce Therapeutics Inc will post 1.64 EPS for the current year.
Jounce Therapeutics Profile
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Read More: Why is the price-sales ratio important?
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.